Related Experiment Videos
Coronary intervention and glycoprotein IIb/IIIa integrin blockade
1Duke Clinical Research Institute, Durham, North Carolina 27710, USA.
Abstract:
In a few short years, platelet glycoprotein IIb/IIIa receptor antagonists have been developed from laboratory curiosities to critical treatment adjuncts to the successful performance of PCI. With more than 15,000 patients participating in trials of these agents during PCI, it is now clear that glycoprotein IIb/IIIa blockade reduces rates of adverse cardiovascular sequelae after PCI. Abciximab is the most extensively studied agent to date, but trials of other antagonists, particularly eptifibatide and tirofiban, support the utility of this class of therapeutic agents as a whole. This paper examines and interprets the results of large-scale clinical trials of glycoprotein IIb/IIIa inhibition during PCI and reviews directions for future study with this unique class of agents.
Insights
Platelet glycoprotein IIb/IIIa receptor antagonists are crucial for reducing adverse cardiovascular events during percutaneous coronary intervention (PCI). Clinical trials confirm their effectiveness, establishing them as vital treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Platelet glycoprotein IIb/IIIa receptor antagonists have rapidly evolved from experimental compounds to essential treatments.
- Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.
Purpose of the Study:
- To examine and interpret results from large-scale clinical trials of glycoprotein IIb/IIIa inhibition during PCI.
- To review future research directions for this class of therapeutic agents.
Main Methods:
- Analysis of data from over 15,000 patients in clinical trials involving glycoprotein IIb/IIIa antagonists during PCI.
- Review of studies on specific agents like abciximab, eptifibatide, and tirofiban.
Main Results:
- Glycoprotein IIb/IIIa blockade significantly reduces adverse cardiovascular sequelae following PCI.
- Abciximab is the most studied agent, but eptifibatide and tirofiban also demonstrate class utility.
Conclusions:
- Glycoprotein IIb/IIIa receptor antagonists are proven effective in reducing cardiovascular complications after PCI.
- Further research is warranted to explore the full potential of these agents.